A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
22/09/2021at 15:47

New Genmab/Seagen drug will cost up to USD 120,000

Patients being treated for cervical cancer in the US will pay a considerable sum to be treated with Genmab and Seagen's newly approved drug Tivdak, which the two companies will market together in the country.
Photo: Lars Møller / Genmab / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN

This week's FDA approval of cervical cancer drug Tivdak is a historic one for Genmab. Although the company does have other approved drugs on the market – Darzalex, Kesimpta and Tepezza – this marks the first time that the company will market one of its own drugs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Joost Melis / Genmab / PR

    Genmab presents "encouraging" data for cervical cancer candidate

    For subscribers

  • Photo: Joost Melis / Genmab / PR

    FDA gives accelerated approval to Genmab and Seagen's cervical cancer drug

    For subscribers

  • Photo: Tuala Hjarnø / Genmab / PR

    Analyst: New Genmab approval shows portfolio potential

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”
  • GN's veteran chairman to retire
  • GN chairman unsure about his board future

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Photo: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Photo: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Photo: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Further reading

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Foto: Euha/foto Rechnitz
Hearing health

New batch of hearing firm recommendations moves GN up, Demant and Sonova down

Jefferies takes stock of hearing aid industry, and comes up with a new string of recommendations.

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Lead Data Architect

  • Commercial Director

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Principal Laboratory Technologist

See all jobs

Jobs

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Lead Data Architect

  • Commercial Director

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Principal Laboratory Technologist

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge